Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.50 |
| ▸ | HTR2B | P41595 | 4/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204913 | 0.87 | HTR2C (0.47) | HTR2CHTR2BHTR2ASLC6A4SLC6A2 | |
| SCHEMBL1254418 | 0.74 | KDM1A (0.45) | HTR2ASLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL1255256 | 0.74 | HTR2C (0.42) | HTR2CHTR2BHTR2AADRB1SLC6A4 | |
| SCHEMBL1254662 | 0.73 | TAAR1 (0.41) | HTR2CHTR2BHTR2AADRB1SLC6A4 | |
| SCHEMBL3549378 | 0.73 | KDM1A (0.42) | HTR2CHTR2BHTR2ASLC6A4SLC6A2 | |
| SCHEMBL10682669 | 0.73 | CHRNB2 (0.37) | HTR2CHTR2BHTR2ACYP2D6 | |
| SCHEMBL1254378 | 0.73 | HTR2C (0.51) | HTR2CHTR2BHTR2AADRB1SLC6A4 | |
| SCHEMBL3549147 | 0.73 | SLC6A2 (0.35) | HTR2CHTR2BHTR2ASLC6A4SLC6A2 | |
| SCHEMBL2203451 | 0.73 | HTR2C (0.41) | HTR2CHTR2BHTR2ASLC6A4SLC6A2 | |
| SCHEMBL7548165 | 0.72 | ADRB1 (0.41) | HTR2CHTR2BHTR2AADRB1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051219-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | HELTON DAVID REED (US) | 2015-02-19 | — | — | US | claimed |
| EP-2558449-B1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-03-05 | — | — | EP | claimed |
| US-8586747-B2 | 3,3-dimethyl tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-11-19 | — | — | US | claimed |
| EP-2558449-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2013-02-20 | — | — | EP | claimed |
| US-20130023518-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | Hoffmann-La Roche Inc (US) | 2013-01-24 | — | — | US | claimed |
| US-8344137-B2 | 3,3-dimethyl tetrahydroquinoline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-01-01 | — | — | US | claimed |
| WO-2011128251-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | WO | claimed |
| US-20110257151-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2011-10-20 | — | — | US | claimed |
| US-20110172242-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2011-07-14 | — | — | US | claimed |
| EP-2285373-A2 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | Cenomed Biosciences, LLC (US) | 2011-02-23 | — | — | EP | claimed |
| WO-2010036395-A2 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | CENOMED BIOSCIENCES, LLC (US) | 2010-04-01 | — | — | WO | claimed |
| US-20090264443-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2009-10-22 | — | — | US | claimed |
| US-20150051219-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | HELTON DAVID REED (US) | 2015-02-19 | — | — | US | disclosed |
| EP-2558449-B1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-03-05 | — | — | EP | disclosed |
| US-8586747-B2 | 3,3-dimethyl tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2558449-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| EP-2285373-A2 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | Cenomed Biosciences, LLC (US) | 2011-02-23 | — | — | EP | disclosed |
| WO-2010036395-A2 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | CENOMED BIOSCIENCES, LLC (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20090264443-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172242-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | DDT, CYP4X1, AHR | HTR2C 56/4885HTR2B 470/4885HTR2A 108/4885 |
| US-20150051219-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | DDT, CYP4X1, AHR | HTR2C 56/4885HTR2B 470/4885HTR2A 108/4885 |
| US-20110257151-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | QDPR, PRMT3, PRMT1 | HTR2C 76/4885HTR2B 331/4885HTR2A 402/4885 |
| US-20130023518-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | QDPR, PRMT3, PRMT1 | HTR2C 76/4885HTR2B 331/4885HTR2A 402/4885 |
| US-20090264443-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | DDT, CYP4X1, AHR | HTR2C 56/4885HTR2B 470/4885HTR2A 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.